The coordinated expression of myogenic regulatory factors, including MyoD and myogenin, orchestrates the steps of skeletal muscle development, from myoblast proliferation and cell-cycle exit, to myoblast fusion and myotubes maturation. Yet, it remains unclear how key transcription factors and epigenetic enzymes cooperate to guide myogenic differentiation. Proteins of the SMYD (SET and MYND domain-containing) methyltransferase family participate in cardiac and skeletal myogenesis during development in zebrafish, Drosophila and mice. Here, we show that the mammalian SMYD3 methyltransferase coordinates skeletal muscle differentiation in vitro. Overexpression of SMYD3 in myoblasts promoted muscle differentiation and myoblasts fusion. Conversely, silencing of endogenous SMYD3 or its pharmacological inhibition impaired muscle differentiation. Genome-wide transcriptomic analysis of murine myoblasts, with silenced or overexpressed SMYD3, revealed that SMYD3 impacts skeletal muscle differentiation by targeting the key muscle regulatory factor myogenin. The role of SMYD3 in the regulation of skeletal muscle differentiation and myotube formation, partially via the myogenin transcriptional network, highlights the importance of methyltransferases in mammalian myogenesis.
Myogenesis is a complex, stepwise process that is initiated by the commitment of precursor cells to the myoblast lineage, followed by cell-cycle arrest and gradual increase in muscle-specific gene expression, leading to terminal differentiation. The process culminates in the fusion of differentiated cells to generate myotubes, essential multinucleated syncytia that underlie the sarcomeric structure and contractile muscle functions. Muscle assembly and function rely on the coordinated expression of muscle-specific proteins that contribute both to muscle structure and to the control of excitation-contraction coupling, needed for force generation 1, 2 . The combined and temporally-controlled action of the Myogenic Regulatory Factor (MRF) family of transcription factors (namely, MyoD, Myf5, Mrf4 and myogenin) together with selected epigenetic modifier enzymes generate highly-specific gene expression profiles required for myogenesis [3] [4] [5] . The MRF basic helix-loop-helix transcription factors bind to E-Box consensus sequences within the regulatory regions of muscle-specific genes 1, 6 . While MyoD, Myf5 and Mrf4 act at the early onset of myogenesis to drive myoblasts formation, myogenin acts later in the cascade of myogenic activation, and is critical for the terminal differentiation of committed muscle cells and myofiber maturation [7] [8] [9] . Myogenin expression is not detected in proliferating myoblasts in culture, but appears early upon induction of differentiation. In Myog −/− knockout mouse embryos, myoblasts are specified to muscle fate, but mice die at birth with severe skeletal muscle defects 10, 11 . Similarly, loss of myog in zebrafish prevents myocytes fusion and formation of muscle fibers 12 . Genome-wide analysis has defined gene expression changes during myogenesis and the profiles of MRF binding upon differentiation 3, [13] [14] [15] . MyoD and myogenin regulate distinct, but overlapping, target genes and act sequentially at individual promoters 16, 17 . Notably, MyoD alone is sufficient to fully activate the expression of early target genes (0-24 h post-differentiation), whereas late-expressed genes (24-48 h post-differentiation) require MyoD to initiate chromatin remodeling that subsequently facilitates myogenin binding and myogenin-mediated transcriptional activation 17 . MyoD can initiate the specification of muscle cell fate due to its capacity to recognize target genes within a native silent chromatin context and to initiate chromatin remodeling at these sites, allowing transcriptional activation [18] [19] [20] . Importantly, MyoD recruits most of the factors required to activate the Myog promoter upon differentiation, including histone methyltransferases (such . Chromatin regulators drive major cell fate decisions, and histone lysine methyltransferases (KMTs) have emerged as key players in development, included cardiac and skeletal muscle formation [23] [24] [25] . Aberrant regulation of these methylation events and alterations in global levels of histone methylation contribute to tumorigenesis and developmental defects 23 . However, our understanding of the role of epigenetic enzymes in myogenesis has lagged behind the characterization of the mechanistic contributions of the MRF transcription factors. The family of SMYD methyltransferases (SET and MYND domain-containing proteins) gained attention as novel myogenic modulators during development 26, 27 . For example, SMYD1, SMYD2 and SMYD4 play roles in cardiac and skeletal muscle differentiation in mouse, zebrafish and Drosophila, but the precise molecular mechanisms and relevant target genes are unknown [28] [29] [30] [31] . The SMYD3 protein is frequently overexpressed in human cancers; it recognizes specific DNA sequences and has been reported to act as an epigenetic regulator through tri-methylation of histone residues H3K4, H4K5 and H4K20 [32] [33] [34] . SMYD3 is required for correct cardiac and skeletal muscle development in zebrafish 35 . Proserpio and colleagues suggested a role for SMYD3 in regulating skeletal muscle atrophy via expression of myostatin, a strong negative regulator of muscle growth 36 . We studied the mechanisms of SMYD3 functions in myogenesis using in vitro myoblast differentiation. We investigated SMYD3 gain-and loss-of-function phenotypes and found that SMYD3 is required for the activation of the key MRF myogenin. Inhibition of SMYD3 expression or activity caused defective skeletal muscle differentiation and myotube formation, whereas SMYD3 overexpression enhanced differentiation and fusion. Transcriptome RNA-Seq analysis of mouse myoblasts upon SMYD3 knockdown (SMYD3 KD ) or SMYD3 overexpression (SMYD3 OE ) revealed a transcriptional network of genes involved in skeletal muscle structure and function. We show that SMYD3 acts upstream of a myogenin transcriptional program that is required for skeletal muscle differentiation.
Results

SMYD3 overexpression enhances myogenic differentiation. Initial analysis showed that SMYD3
transcript and protein are expressed in proliferating, undifferentiated myoblasts and stably maintained throughout differentiation of either murine or human myoblasts ( Supplementary Information, Fig. S1A-D) . To explore a role in myogenic differentiation, we overexpressed SMYD3 in C2C12 murine myoblasts using retroviral infections of HA-FLAG-tagged SMYD3. We generated two independent clonal cell lines, referred to as SMYD3 CL3 and SMYD3 CL5, and studied differentiation and myotube formation upon transfer to conventional differentiation media (DM). SMYD3-overexpressing (SMYD3 OE ) clones formed morphologically larger, multinucleated myotubes, compared to control cells (Fig. 1A,B) . SMYD3 overexpression caused premature and elevated expression of differentiation markers, such as Muscle Creatine Kinase (MCK) and Myosin Heavy Chain (MyHC) compared to the controls (Fig. 1C) . RNA expression analysis revealed a marked upregulation of Mck and the fusion gene Mymk, as well as genes encoding components of the contractile apparatus (e.g. Tnnc1, Myh3, Myl4, Atp2a1) ( Fig. 1D and Supplementary Information, S1E ). Hence, SMYD3 overexpression enhanced myogenic differentiation and myotube formation, with premature appearance of muscle differentiation markers and the formation of larger, multinucleated myotubes. These results suggest that SMYD3 is a positive regulator of myoblast differentiation.
SMYD3 knockdown impairs myogenic differentiation.
To explore whether SMYD3 is required for skeletal myogenesis, we knocked-down SMYD3 expression in undifferentiated myoblasts by small interfering RNAs (siRNAs), and analyzed myogenic phenotypes. Knockdown of SMYD3 (SMYD3 KD ) severely impaired C2C12 differentiation; siSMYD3-transfected myoblasts remained predominantly as individual mononucleated cells, compared to the morphologically distinctive multinucleated myotubes in siControl ( Fig. 2A) . SMYD3 knockdown impaired myotube formation (even after 72 h in DM), reduced the size and number of MyHC-positive cells, and decreased the fusion index and myotube diameter compared to control cells ( Fig. 2A,B) . SMYD3 KD cells exhibited significantly reduced levels of both MyHC and MCK proteins during a 3-day differentiation experiment (Fig. 2C) . Because the transcriptional landscape dramatically changes during the first 24 hours of myoblast differentiation 7 , we assessed whether SMYD3 silencing could impair transcription of the early myogenic cascade. We analyzed mRNA expression of myogenic differentiation factors in early differentiating C2C12 cells upon SMYD3 silencing. siSMYD3 significantly attenuated the transcriptional activation of myogenic markers (e.g. Mck, Tnnc1, Myh3, Myl4, Atp2a1, and Mymk) at 24 h post-differentiation, compared to control cells (Fig. 2D ). These observations were confirmed with a second independent siRNA oligo, siSMYD3#2 ( Supplementary Information, Fig. S2A-E) . We observed a similar delay in myogenic differentiation in primary murine myoblasts, with decreased MCK and MyHC protein levels in SMYD3 KD cells, compared to siCtrl control ( Supplementary Information, Fig. S2F ). These data demonstrate that transient SMYD3 knockdown prevented correct myogenic differentiation in murine myoblasts, delayed expression of key muscle differentiation markers and strongly impaired myoblast fusion. Additional experiments with human immortalized myoblasts, showed that SMYD3 is expressed in both undifferentiated and differentiated human cells ( Supplementary Information,  Fig. S1C,D) . siRNA knockdown of human SMYD3 also impaired myogenic differentiation, reducing protein levels of MCK and MyHC markers ( Supplementary Information, Fig. S3A ). We extended these results by stable and sustained SMYD3 silencing using CRISPRi technology 37 . Again, SMYD3-silencing (sgSMYD3) caused a delay in myogenic differentiation, and marked downregulation of MCK protein levels compared to controls (sgCtrl) ( Supplementary Information, Fig. S3B ,C) with a significant reduction in MCK and muscle actin ACTA1 RNA levels ( Supplementary Information, Fig. S3D ). To rule out clonal SMYD3 OE effects, we performed additional experiments to show that siSMYD3 reversed MyHC staining, differentiation marker expression, myotube size and the differentiation potential of SMYD3 OE cells ( Supplementary Information, Fig. S3E-G) . These results exclude possible clonal effects, and showed that SMYD3 knockdown could counteract the enhancement of myogenesis observed in SMYD3 OE clones. Other members of the SMYD protein family of lysine methyltransferases including SMYD1, 2 and 4 are implicated in skeletal and cardiac differentiation in different model organisms 28, 30, 31 . We tested whether Smyd1, Smyd2 and Smyd4 mRNA levels were affected in SMYD3 KD cells. Interestingly, we www.nature.com/scientificreports www.nature.com/scientificreports/ found that only the expression of the multifunctional myogenic activator Smyd1 was significantly reduced upon SMYD3 silencing ( Supplementary Information, Fig. S3H ). Likewise, Smyd1 transcript levels were also strongly upregulated in SMYD3 OE cells, whereas mRNA levels of both Smyd2 and Smyd4 were unaffected ( Supplementary  Information, Fig. S3H ). Overall, these loss-of-function experiments demonstrate that SMYD3 is required for appropriate myogenic transcriptional activation, myoblast fusion and myotube formation. SMYD3 KD in myoblasts caused deregulated expression of differentiation markers and defective terminal differentiation.
Pharmacological inhibition of SMYD3 decreases myogenic differentiation potential. BCI-121
is a novel SMYD3 small-molecule inhibitor that specifically reduces SMYD3 activity, by competing with histones for binding to SMYD3 and preventing its recruitment to the promoter region of target genes 38 . To explore further SMYD3 function in myogenesis, we cultured and differentiated C2C12 cells with medium that contained 100 µM of BCI-121, or DMSO control, and analyzed MyHC and MCK markers expression by western blot analysis. BCI-121 treatment significantly decreased the differentiation efficiency, recapitulating the effects observed upon transient SMYD3 knockdown (Fig. 2E ). This inhibitory effect was also validated in SMYD3 OE cells ( Supplementary  Information, Fig. S3I ). Hence, SMYD3 pharmacological inhibition using the BCI-121 inhibitor significantly reduced myoblast differentiation potential, supporting a role for SMYD3-mediated methylation in myogenesis.
SMYD3 does not influence myoblast proliferation. Myogenic terminal differentiation requires a deli-
cate balance between proliferation and differentiation, involving permanent exit from the cell cycle and concomitant activation of a muscle-specific genetic program. Consequently, factors that regulate cell cycle progression can inhibit myogenic differentiation by preventing cell cycle exit 39 . SMYD3 is frequently overexpressed in cancer cells and enhances cell proliferation 32 . It was therefore important to determine whether SMYD3-dependent effects on muscle differentiation result from altered proliferative signals and impaired cell cycle arrest upon mitogen withdrawal. We observed no differences in the global number of cells in SMYD3 KD or SMYD3 OE myoblasts following induction of differentiation, compared to controls. To evaluate the impact of SMYD3 on myoblast proliferation and cell cycle arrest, we performed EdU incorporation analysis in C2C12 cells and measured the percentage of EdU-positive nuclei in growth medium (GM) and after 24 h in Differentiating media (DM). These experiments showed comparable percentages of EdU-positive cells in both SMYD3 OE and SMYD3 KD cells and controls, in both proliferating and differentiating conditions (Fig. 3A,B and Supplementary Information, Fig. S4A,B) . Furthermore, Cyclin D1 and cyclin-dependent kinase inhibitor 1 p21 protein levels were not affected by SMYD3 KD or SMYD3 OE (Fig. 3C,D) . Thus, SMYD3 is not implicated in cell cycle regulation in myoblasts and SMYD3-associated differentiation phenotypes are uncoupled from cell cycle exit.
SMYD3 regulates genes associated with myogenic differentiation. SMYD3 has been linked to active histone marks associated with euchromatin formation and we observed that SMYD3 levels in myoblasts affect expression of key differentiation markers early upon muscle differentiation. To define SMYD3-dependent molecular pathways and target genes, we performed RNA-Seq analysis of undifferentiated (0 h) and differentiated (24 h) C2C12 myoblasts SMYD3 KD or SMYD3 OE cells. We compared two different siRNA SMYD3 (siSMYD3#1 and siSMYD3#2) with control siRNA (siCtrl). And we compared SMYD3 OE SMYD3 CL5 cells with control cell lines. We identified 5013 genes (1096 genes up and 3917 genes down) that were differentially expressed between undifferentiated (0 h) and differentiated (24 h) C2C12 siCtrl myoblasts. Gene Ontology (GO) analysis of differentially expressed genes confirmed enrichment in skeletal muscle development and cell cycle progression (not shown). Among the 5013 genes whose expression changes upon differentiation at 24 h in the control myoblasts, we found 311 genes whose expression appeared to be SMYD3-dependent (107 upregulated and 204 downregulated genes) (Supplementary Information, Table S1 ). We performed enrichment analyses using the Gene Ontology Enrichment Analysis tool (http://geneontology.org/). Downregulated genes were enriched for GO terms associated with skeletal muscle development and muscle contraction, whereas upregulated genes were enriched for cell adhesion, cell division and cell migration genes. Conversely, SMYD3 OE cells show 836 genes whose expression appeared to be SMYD3-dependent at 24 h post differentiation (412 upregulated and 424 downregulated genes) (Supplementary Information, Table S2 ). These upregulated genes highlighted skeletal muscle development, actin organization, sarcomeric structures and muscle contraction processes. Downregulated genes were mainly related to cell motility, cell adhesion and cell communication and signaling. To focus on potential SMYD3 target genes, we identified common deregulated genes between SMYD3 KD and SMYD3 OE cells at 24 h post-differentiation. These 72 differentially-expressed genes exhibited a strong anti-correlation between SMYD3-loss and gain of function cell systems ( Fig. 4A and Supplementary Information, Table S3 ) and were enriched for genes involved in skeletal muscle development, contraction and cell migration or positioning (Fig. 4B) . Further analysis revealed three main classes of biological functions: (i) gene families coding for structural sarcomeric proteins required for myofibril assembly, for example myosin light chain (MYL1, MYL4, MYL6B, MYLPF), myomesins (MYOM1, MYOM2, MYOM3) and Troponins (TNNI1, TNNI2, TNNT1, TNNT3), (ii) genes encoding calcium pumps and calcium binding proteins required for muscle excitation and contraction (e.g. ATP2A1, Sarcalumenin, RYR1, RYR3), and (iii) genes encoding proteins involved in cell-extracellular matrix interactions (e.g. MMP10, SGCA). The list also includes three genes involved in myoblast fusion; the muscle-specific Ser/Arg-rich protein specific kinase 3 (SRPK3), the Kelch-like protein 41 (KLHL41) and the myoblast fusion protein Myomaker (Mymk). Interestingly, we observed deregulated expression of the MRF myogenin, a key regulator of skeletal muscle differentiation; myogenin was markedly reduced in SMYD3 KD cells and significantly elevated in SMYD3 OE cells, at 24 h post-differentiation compared to control cells. Notably, myogenin was the only transcription factor on this list of differentially expressed genes. Hence, the genome-wide expression profiling of differentiating C2C12 cells suggested that SMYD3 could participate in an early cascade of transcriptional activation (0-24 h) and that genes important for muscle formation and activity are impacted by SMYD3. Our www.nature.com/scientificreports www.nature.com/scientificreports/ analysis also raised the possibility that deregulated myogenin expression might account for the defects in muscle gene expression and differentiation. Myogenin target genes have been widely studied 3, 17, [40] [41] [42] . To test this hypothesis, we compared the SMYD3-dependent differentially expressed genes with a published list of myogenin target genes reported for myogenin knockdown studies (#GSE19967) 43 . We identified 894 genes differentially expressed upon myogenin knockdown in C2C12 cells at 24 h post-differentiation (p-value cut-off of 0.01, following ID microarray conversion) ( Supplementary Information, Table S4 ). Of these, 37 genes were differentially regulated in our SMYD3 KD dataset (i.e. 11.8% of differential genes in siSMYD3 C2C12 at 24 h post-differentiation), and this enrichment is statistically significant (p = 8.19 e-17 by hypergeometric distribution test). Conversely, 41 of these myogenin-dependent genes were in common with our SMYD3 OE C2C12 dataset (i.e. 4.9% of SMYD3 OE C2C12 genes) ( Supplementary Information, Table S4 ). Again, this enrichment is significant (p = 1.78 e-06 by hypergeometric distribution test). Thus, the expression of myogenin-regulated genes correlated with SMYD3 KD , and were anti-correlated with SMYD3 OE datasets ( Fig. 4C and Supplementary Information, Fig. S5C,D) . Surprisingly, only 11 genes were in common within the three datasets, including myogenin itself and the myogenin target Mymk (Fig. 4D,E) . Our findings show that SMYD3-differentially expressed genes display a myogenin-transcriptional signature and support a model in which the deregulated transcriptional program in SMYD3 KD and SMYD3 OE cells is due to defective activation of the myogenin pathway.
SMYD3 is necessary to induce myogenin expression upon differentiation. Our study showed SMYD3-dependent changes in myogenin expression levels following SMYD3 silencing or overexpression in murine and human myoblasts (Fig. 5A,B, Supplementary Information Fig. S6A ). Furthermore, aberrant activation of Myogenin expression was also observed after SMYD3 pharmacological inhibition, both in wild-type C2C12 and in SMYD3 overexpressing cells (Supplementary Information Fig. S6B ). Myogenin expression is tightly regulated during differentiation through chromatin modifications on its promoter and a positive autoregulation loop 41 . Publicly available chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq) ENCODE data showed that the myogenin locus is enriched for H3K4me3 upon myogenic activation and that myogenin binds to its own promoter upon differentiation (Fig. 5C ). SMYD3 was reported to control gene expression through H3K4 di/tri-methylation of the promoters of specific target genes 32 . We performed ChIP analysis of H3K4me3 levels on the myogenin locus to assess whether SMYD3 affects histone methylation levels. SMYD3 KD cells exhibited Supplementary Fig. S7D. www.nature.com/scientificreports www.nature.com/scientificreports/ decreased H3K4me3 levels on the myogenin gene upon differentiation, whereas promoter and distal regions were not affected (Fig. 5D,E) . Conversely, H3K4me3 levels increased significantly on the same region in SMYD3 OE cells compared with controls (Fig. 5F ). SMYD3 can bind to DNA containing 5'-CCCTCC-3' or 5'-GAGGGG-3' sequences on the regulatory regions of target genes 32 , and analysis of the myogenin locus revealed the presence of multiple SMYD3 binding sites, both upstream and downstream of the myogenin transcription start site (TSS). However, we could not detect any significant binding of SMYD3 to the myogenin locus (data not shown). Our data suggest that although SMYD3 is required for myogenin transcriptional activation and is associated with H3K4me3 changes, SMYD3 action might still be indirect. Activation of myogenin expression at early stages of skeletal muscle differentiation is essential for myogenic progression and myogenin controls the expression of late muscle genes by cooperating with other transcription factors 41 . Therefore, we tested whether exogenous myogenin expression could rescue the myogenic potential of SMYD3 KD C2C12. Myogenin ectopic expression partially rescued myotubes formation in siSMYD3 cells, (Fig. 5G,H, Supplementary Information Fig. S6C ). Overall, these findings show that SMYD3 is required for myoblast differentiation through activation of myogenin transcriptional program and also via a myogenin-independent pathway. 
Discussion
Studies of SMYD3 methyltransferase established a role in promoting cancer cell proliferation, invasion and metastasis. Some of these cancer phenotypes were attributed to regulation of specific target genes including WNT10B 44 , hTERT 45 , NKX2.8 32 , MMP9 46 , and homologous recombination (HR) repair genes 47 . While most of the previous work on SMYD3 has focused on its implication in cancer, its role in normal differentiation programs has been largely ignored. The emerging interest in the impact of epigenetic regulators in differentiation has implicated members of the SMYD methyltransferase family in cardiac or skeletal myogenesis during development. These recent findings drove us to explore the molecular mechanisms and target gene pathways of SMYD3 during mammalian, skeletal muscle differentiation. We assessed the role of SMYD3 in mammalian myogenesis by analyzing the consequences of SMYD3 overexpression (SMYD3 OE ) and SMYD3 knockdown (SMYD3 KD ) on myoblast differentiation and gene expression. SMYD3 was originally linked to myogenesis by its requirement for cardiac and skeletal muscle development in zebrafish 35 . Our data provide the first evidence for a role of SMYD3 as a positive regulator of myogenic differentiation in mammals, as well as the first SMYD3-dependend transcriptomic analysis in differentiating myoblasts. We show that SMYD3 OE enhanced muscle differentiation in murine myoblasts, characterized by elevated expression of differentiation markers and increased myotubes size (Fig. 1) . Conversely, SMYD3 KD hampered the expression of differentiation markers and impaired myogenic differentiation in vitro (Fig. 2) . Our transcriptome analysis identified SMYD3-dependent genes with important roles in skeletal muscle development, structure, organization and function (Fig. 4) . Furthermore, our loss-of-function analysis highlighted the conservation of SMYD3 function between human and mouse and supports an evolutionary conserved role for SMYD3 in myogenesis. Besides, we showed that the SMYD3 inhibitor BCI-121 significantly reduced C2C12 differentiation potential, supporting the importance of SMYD3 catalytic methyltransferase activity for proper myogenesis. Contrasting observations linking SMYD3 to muscle atrophy through the transcriptional activation of c-Met and myostatin genes 36 , suggest that SMYD3 could play diverse roles in normal development and in response to physiological stress, such as atrophy. Myogenesis requires a tightly-regulated balance between irreversible cell cycle exit, induction of muscle-specific genes, and functions of epigenetic regulators (for example, the SWI/SNF chromatin remodeling complex) 40, 48, 49 . SMYD3's role in cancer involves regulating cell proliferation and cell cycle progression 32, 50, 51 . So it was important to establish whether the muscle differentiation phenotypes could be explained by deregulation of cell cycle genes in SMYD3 OE or SMYD3 KD cells. Our proliferation analysis showed that SMYD3 is not primarily involved in the regulation of myoblasts cell cycle progression and cell cycle exit upon differentiation (Fig. 3) , thereby uncoupling myoblast proliferation from SMYD3-dependent differentiation roles.
Our study takes SMYD3 beyond cancer functions and links with recent reports implicating SMYD3 as a developmental regulator. For example, Smyd3 expression is induced during human ES cell differentiation 52 and SMYD3 contributes to early embryonic lineage commitment, where it participates in the blastocyst induction of pluripotency genes (Oct4, Nanog, Sox2), primitive endoderm markers (such as Gata6) and trophoectoderm markers (Cdx2 and Eomes) 53 . Furthermore, SMYD3 maintains the self-renewal capacity of a subset of cancer stem cells (CSCs) by regulating the expression of the master stem cell regulator ASCL2 54 . SMYD3 was detected in both undifferentiated and differentiated myoblasts and is not induced upon differentiation ( Supplementary  Information Fig. S1 ). Furthermore, SMYD3 expression is detected in mesenchymal stem cells, from which the myogenic lineage derives (data not shown). Thus, it will be interesting to investigate if Smyd3 is required for early commitment to muscle cell identity and the de-repression of developmental regulators. Our transcriptomic analysis revealed that changes in SMYD3 levels primarily affect the expression of the key MRF myogenin and muscle-specific genes, suggesting that SMYD3 acts upstream of myogenin upon myoblast differentiation.
The activation of myogenin expression is required for the myogenic program, both during muscle development and post-natal muscle growth 11, 40, 55 . Myogenin expression is directly regulated by MyoD, which can recognize E-box sequences in myogenin regulatory regions and can interact with chromatin remodeling factors and transcriptional regulators to drive expression 6, 8 . MyoD recruits histone acetylases (HATs) and the SWI/SNF remodeler complex to the myogenin locus 18, 19 . The KMT Set7/9 positively regulates myogenesis via interaction with MyoD and H3K4 methylation at regulatory regions of muscle genes 22 . Myogenin can also regulate its own expression via a positive feed-back loop 41 . Our transcriptome analysis showed that myogenin was the only MRF whose expression was significantly affected in both SMYD3 KD and SMYD3 OE cells, at 24 h post-differentiation (Fig. 4) . Furthermore, our ChIP experiments demonstrated that the deposition of the active transcription mark H3K4me3 at the myogenin locus is partially SMYD3-dependent, thus suggesting that SMYD3 is an additional epigenetic factor contributing to the transcriptional activation of myogenin upon myogenesis. However, it is possible that this regulation is through direct or indirect mechanisms. Indeed, we could not detect direct recruitment and binding of SMYD3 at the myogenin locus upon differentiation, nor evidence for a physical interaction with MyoD (unpublished data). In addition to its histones methylation activities, SMYD3 can facilitate mRNA transcription via other mechanisms, including direct interaction with Pol II and the transcriptional cofactors PC4 and BRD4 36, 56 . Hence, we cannot exclude that the SMYD3 regulation of myogenin could also occur indirectly, via these alternative mechanisms.
Among the MRFs, myogenin is essential to guide terminal differentiation, myofiber formation and size 12 . Myoblasts fusion is guided by specific fusion proteins, such as the recently identified Myomaker and Myomerger 57, 58 , whose expression is under myogenin control. We observed substantially fewer multinucleated myotubes in SMYD3 KD cells compared to controls (Fig. 2) , whereas SMYD3 OE increased the number of MHC positive cells and the size of formed myotubes (Fig. 1) . Furthermore, our transcriptomic analysis detected SMYD3-dependent changes in the expression of genes involved in myoblast fusion, including the key fusion protein Myomaker. Thus, SMYD3 might regulate the expression of muscle-specific genes at the onset of differentiation, but also the later myoblast fusion processes necessary for correct terminal differentiation. www.nature.com/scientificreports www.nature.com/scientificreports/ C2C12 might depend on the lack of myogenin 10, 11 . Our transcriptome analysis highlighted that myogenin target genes are differentially expressed in SMYD3 KD and SMYD3 OE cells (Fig. 4) . It will be important to further investigate whether SMYD3 directly regulates the expression of genes involved in myoblast fusion, or whether this is an indirect effect of the deregulation of early myogenesis events, notably myogenin transcriptional activation.
Our data using myoblast models show that SMYD3 positively affects myogenesis. However, Smyd3 −/− mice are viable with no clear developmental defects 59 . This might be explained by compensation in vivo mediated by proteins with redundant functions. The SMYD protein family counts five different members which share a common conserved structure and some common histone targets, which may ensure redundancy during development 60 . Furthermore, studies have implicated SMYD1-4 in cardiac and skeletal muscle development 26, 27 . SMYD1 is the only member showing a muscle-restricted pattern of expression 28, 61 . We observed that Smyd1 transcript levels were affected in both SMYD3 KD and SMYD3 OE cells ( Supplementary Information, Fig. S3 ). Previous studies revealed that Smyd1 expression is directly regulated by myogenin 61 , suggesting that changes in Smyd1 expression are likely to be due to defective activation of myogenin upon SMYD3 expression modulation. Finally, we show that myogenin ectopic expression partially rescues terminal differentiation of SMYD3 KD C2C12, suggesting that SMYD3 and myogenin affect myoblasts fusion through overlapping and also distinct mechanisms.
Our findings support a model in which SMYD3 can function upstream of a myogenin-dependent regulatory network, to regulate (directly or indirectly) endogenous myogenin expression. Both SMYD3 KD and SMYD3 OE phenotypes can be explained, at least partially, by the abnormal activation of endogenous myogenin expression, leading to inhibited or enhanced differentiation, respectively. However, only a subset of the deregulated genes in SMYD3 OE and SMYD3 KD cells can be explained by deregulated myogenin expression, highlighting the presence of a myogenin-independent SMYD3 regulatory pathway. In conclusion, our results highlight a new role for SMYD3 as a regulator of the myogenin pathway during muscle differentiation, potentially via its histone methyltransferase activity. We demonstrated that SMYD3 is a positive regulator of murine muscle differentiation, and this action is uncoupled from cell cycle exit, and we provided evidence for a conservation of its role in human myoblasts. Collectively, our data provide novel insights on the role of the lysine methyltransferase SMYD3 in the control of myogenic differentiation and muscle-specific gene expression.
Methods
Cell lines and culture conditions. C2C12 mouse myoblasts were cultured in Growth medium (GM):
Dulbecco's modified Eagle's medium (DMEM, Sigma) supplemented with 15% Fetal Calf Serum (FCS, Gibco) and 100 U/ml penicillin/streptomycin. Primary mouse myoblasts were cultured in plates coated with Gelatine 1%, in GM: DMEM supplemented with 20% FCS, 1% L-glutamine, 100 U/ml penicillin/streptomycin and 2% UltroserG. Muscle differentiation was induced by switching to serum-deprived differentiation medium (DM): DMEM, supplemented with 2% Horse Serum (Gibco), and 100 U/ml penicillin/streptomycin. Likewise, immortalized human myoblasts C25 were grown in GM: 1 Vol medium 199 (Gibco) + 4 Vol DMEM GlutaMAX (Gibco), 20% FCS, Fetuin: 25 µg/ml, hEGF: 5 ng/ml, bFGF: 0,5 ng/ml, Insulin: 5 µg/ml, Dexamethasone: 0,2 µg/ml, 100 U/ ml penicillin/streptomycin. Differentiation was induced by switching to serum-deprived DM (DMEM + 100 U/ ml penicillin/streptomycin + 10 μg/ml Insulin). All cell lines were cultured at 37 °C and 5% CO 2 . Primary murine myoblasts were isolated from adult murine skeletal muscle and were kindly provided from Dr A. Pincini (Institut Cochin). C25 cells were provided by Dr A. Bigot (Institut de Myologie). All cell lines were cultured at 37 °C and 5% CO2. The SMYD3 small-molecule inhibitor BCI-121 (Sigma, SML1817) was dissolved in DMSO at a concentration of 20 mg/ml. C2C12 cells were cultured for 24 h in GM containing 100 µM of BCI-121 or DMSO as a negative control. Cells when then switched to DM containing 100 µM of BCI-121 or DMSO for 72 hrs. Protein samples were harvested at 0, 24, 48 and 72 h post-differentiation upon BCI-121 treatment and analyzed by western blot for differentiation markers expression.
Transfection and gene silencing. C2C12 cells, primary mouse myoblasts and human immortalized myoblasts were transfected with 60 nM final of siRNAs (Sigma Aldrich) using LipoRNAiMAX (Invitrogen), according to the manufacturer's instructions. Two consecutive transfections were performed, the first one on proliferative non confluent myoblasts and the second one 24 h later, when myoblasts were induced to differentiation. The specific oligo sequences of siRNA are listed in Supplementary Table S6 . Plasmids expressing MYOGENIN in pEMSV vector were kindly provided by the laboratory of Dr S. Ait-Si-Ali (CNRS, UMR7216, Paris) and transfected in C2C12 at 0.1 µg/cm 2 using Lipofectamine2000 (Invitrogen) according to the manufacturer's instructions.
Construction of C2C12 cell line stably expressing HA-Flag-SMYD3. The cDNA encoding SMYD3
was PCR amplified and cloned into the pREV retroviral vector, kindly obtained from the laboratory of Dr S. Ait-Si-Ali (CNRS, UMR7216, Paris). The plasmid contains an epitope tag (3 HA-and 3 Flag-tag) in 5' of the cloning site and a selection marker. C2C12 myoblasts stably expressing double-tagged Flag-HA-SMYD3 protein were established using retroviral transduction strategy as previously described 48 . C2C12 cells stably integrating pREV-SMYD3 or pREV control vector were sub-cloned to obtain 100% positive clonal populations. Stable ectopic SMYD3 expression in these clones was validate by western blot and immunofluorescence analysis, using anti-HA and anti-FLAG antibodies. We selected two C2C12 positive clonal populations for our further experiments, called SMYD3 CL3 and SMYD3 CL5.
CRISPRi design and lentiviral transduction. Human immortalized myoblasts C25 were transduced with lentiviral particles encoding CRISPRi system as previously described 37 . Briefly, sgRNAs were designed to target near the TSS of the gene of interest (100 bp upstream) and cloned into pLKO5-sgRNA-EFS-tRFP vector. pHR-SFFV-dCas9-BFP-KRAB plasmid was used for KRAB-dCas9 expression. To produce lentiviral particles, 293 T cells were co-transfected with an envelope plasmid (pMD2.G-VSV-G), a packaging vector (psPAX2) and (2019) 9:17298 | https://doi.org/10.1038/s41598-019-53577-5 www.nature.com/scientificreports www.nature.com/scientificreports/ (Kindly provided by Dr Slimane Ait-si-Ali, raised by Dr H Ito), rabbit anti-SMYD3 (Abcam, ab187149), rabbit anti-SMYD3 (Diagenode, C15410253-100), rabbit anti-Cyclin D1 (Abcam, ab 16663), rabbit anti-P21 (ab 109199), mouse anti-MYOGENIN (F5D ab 1835).
Immunofluorescence and EdU staining. For each experiment, at the indicated time point, cells were washed with phosphate buffered saline (PBS) and fixed in PBS 3.7% formaldehyde for 15 min at room temperature. Cells were rinsed twice in PBS, permeabilized with PBS 0.5% Triton X-100 for 5 min and then blocked for 30 min with PBS 1% BSA to prevent non-specific staining. After three washes in PBS 0.2% Tween-20, cells were incubated with primary antibodies in 1% BSA at room temperature for 40 min -1h. After washing in PBS 0.2% Tween, cells were incubated for 30 min with secondary antibodies (1:500). Following washing in PBS 0.2% Tween, cells were stained with Hoechst or directly mounted using ProLong ™ Gold Antifade Mountant with DAPI (Thermo Scientific). Images of immunofluorescence staining were photographed with a fluorescent microscope Leica Inverted 6000 or Zeiss, using Metamorph or ZEN software, respectively. As primary antibody we used anti-MyHC antibody (R&D Systems, MAB4470) and anti-MyoG antibody (F5D supernatant from DSHB). As secondary antibody Alexa Fluor 488 Goat anti-mouse or Cy3 Goat anti-mouse, of different IgG subtypes when co-staining for MyoG/MyHC. Fusion index was calculated as the percentage of nuclei contained in MyHC-positive myotubes, compared to the total number of nuclei. Myotubes diameter was measured along the myotube using ImageJ. Cell proliferation was assessed using EdU assay. C2C12 and stable clones were plated and induced to differentiation, or transfected with siRNAs before induction of differentiation. EdU incorporation was monitored in two culture conditions: GM or 24 h in DM. EdU was added in cell culture media at a final concentration of 10 µM during 30 min (at 37 °C). Cells were washed in PBS and fixed in PBS 3.7% formaldehyde for 15 min. After washing in PBS, cells were permeabilized in PBS Triton X-100 0.5% for 15 min. Cells were washed three times in PBS Tween 0.2% and stained using the Click-iT ® EdU Alexa Fluor ® 488 kit (Thermo Scientific), following manufacturer's instruction. Cells were incubated for 1 h at room temperature, followed by three washes in PBS. Cells were then fixed in PBS 3.7% formaldehyde for 10 min, washed three times in PBS, permeabilized in PBS Triton X-100 0.5% for 5 min. After washes in PBS, cells were stained with DAPI and analysed with a fluorescent microscope (Leica Inverted 6000). EdU and DAPI staining were counted in three independent experiment per condition. % EdU positive cells was calculated as the ration of EdU positive nuclei to DAPI-labeled nuclei.
Statistical analysis. Statistical analysis were performed using GraphPad Prism 7.0 software. The data were subjected to statistical tests as specified in the figure legends. Error bars show standard error means (SEM). P values of less than 0.05 were considered as statistically significant.
Data availability
All data generated or analyzed during this study are included in this published article. The RNA-Sequencing data have been deposited to the GEO with the dataset identifier GSE137954.
